Items Tagged ‘Metastatic Breast Cancer’

October 26th, 2016

Ribociclib Offers ‘Paradigm Shift’ in Advanced Breast Cancer

By

The investigational drug ribociclib (formerly LEE011) when combined with Femera (letrozole) for the initial treatment of postmenopausal women with hormone-receptor positive (HR+) metastatic breast cancer leads to improved survival without cancer recurrence. The interim results from a large clinical trial presented at the 2016 European Society for Medical Oncology (ESMO) meeting and published in the […]

View full entry

Tags: 2016, Breast Cancer, ESMO, Femera, hormone-receptor positive, HR+ metastatic, letrozole, Metastatic Breast Cancer, MONALEESA-2 clinical, News, ribociclib LEE011


September 5th, 2016

ASCO Treatment Recommendations for HR+, Metastatic Breast Cancer

By

The American Society of Clinical Oncology (ASCO) recently convened an Expert Panel to create recommendations for endocrine therapy for women with hormone-receptor (HR)-positive, metastatic breast cancer. The panel conducted “a systematic review of evidence from 2008 through 2015 to create recommendations informed by that evidence.” These updates were recently published in the Journal of Clinical […]

View full entry

Tags: Breast Cancer, Endocrine therapy, hormone-receptor (HR)-positive, hormones, metastatic, Metastatic Breast Cancer, News, recommendation


June 30th, 2016

Tecentriq™ Plus Abraxane® Effective Combo in Difficult to Treat Breast Cancer

By

The combination of the immune stimulating agent Tecentriq™ (atezolizumab), plus the chemotherapy agent Abraxane® (nab-paclitaxel) is effective in providing anti-cancer responses among patients with advanced triple-negative breast cancer (TNBC). These results were recently reported at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO). Approximately 10-20% of breast cancers are referred to […]

View full entry

Tags: Breast Cancer, immunotherapy, Metastatic Breast Cancer, News, Recurrent Breast Cancer, Tecentriq, tnbc, Triple Negative Breast Cancer


June 22nd, 2016

Directly Involving Patients Drives Participation in Metastatic Breast Cancer Study

By

A clinical study to accelerate research in metastatic breast cancer has rapidly enrolled participants through direct collaboration with patients. These results were recently presented at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO). One large challenge in furthering research in the field of cancer is obtaining enough samples of tumor tissue […]

View full entry

Tags: Breast Cancer, clinical study, Metastatic Breast Cancer, News, Recurrent Breast Cancer


June 7th, 2016

Abemaciclib Promising in Advanced Breast Cancer

By

The investigative agent abemaciclib, which is still in clinical trials, appears promising in providing anti-cancer activity among patients with metastatic breast cancer that has progressed following several prior therapies. These results were recently presented at the 2016 annual meeting of the American Society of Clinical Oncology. Metastatic breast cancer (MBC) refers to cancer that has […]

View full entry

Tags: 2016, abemaciclib, asco, Breast Cancer, HER2-negative, HR-positive, MBC, Metastatic Breast Cancer, MONARCH 1 trial, News


March 28th, 2016

Dose-Dense Chemotherapy for Premenopausal Breast Cancer Improves Survival

By

Premenopausal women who have been diagnosed with breast cancer have improved survival if their chemotherapy doses are delivered every two weeks, compared to every three weeks. These results were recently presented at the 2016 European Breast Cancer Conference (EBCC-10) in the Netherlands. Chemotherapy following surgery is a standard treatment option for premenopausal women diagnosed with […]

View full entry

Tags: Breast Cancer, clinical trials, dose-dense, Metastatic Breast Cancer, News, premenopausal, research, Stage I Node Negative Breast Cancer, Stages II-III Breast Cancer


March 17th, 2016

Ibrance® Approved for Use in Combination with Faslodex® in Hormone-Positive Breast Cancer

By

The United States Food and Drug Administration (FDA) has approved Ibrance (palbociclib) to be used with Faslodex (fulvestrant) for women with hormone-positive (HR-positive), human epidermal growth factor receptor-2 (HER2)-negative, metastatic breast cancer that has progressed following prior endocrine (hormone) therapy. The majority of breast cancers are HR-positive. These cancers are stimulated to grow by the […]

View full entry

Tags: approval, Breast Cancer, Faslodex, fda, fulvestrant, HER2-negative, hormone-positive, Ibrance, metastatic, Metastatic Breast Cancer, News, palbociclib


January 25th, 2016

ASCO Publishes Breast Cancer Survivorship Guidelines

By

The American Society of Clinical Oncology (ASCO), in collaboration with the American Cancer Society (ACS), have released updated guidelines regarding follow-up care for breast cancer survivors. The updated guidelines were recently published in the Journal of Clinical Oncology. There is an estimated 3.1 million breast cancer survivors alive today in the United States. At present, […]

View full entry

Tags: ACS, American cancer society, American Society of Clinical Oncology, Breast Cancer, Carcinoma In Situ Breast cancer, follow-up, guidelines, Inflammatory Breast Cancer, Metastatic Breast Cancer, News, Recurrent Breast Cancer, Screening/Prevention Breast Cancer


January 6th, 2016

Conjugate Drug Extends Survival in Patients with Advanced HER2-Positive Breast Cancer

By

Patients with metastatic, HER2-positive breast cancer who received a combination antibody/chemotherapy drug in a phase 3 clinical trial survived longer, on average, than patients receiving other treatments. Researchers from Dana-Farber Cancer Institute reported the findings at the 2015 San Antonio Breast Cancer Symposium. The TH3RESA trial, which enrolled more than 600 participants in the U.S. […]

View full entry

Tags: antibody, Breast Cancer, Chemotherapy, combination therapy, HER2-positive, meastatic breast cancer, Metastatic Breast Cancer, News, T-DMI, TH3RESA trial, trastuzumab emtansine


January 3rd, 2016

Conjugate Drug Extends Survival in Patients with Advanced HER2-Positive Breast Cancer

By

Patients with metastatic, HER2-positive breast cancer received a combination antibody/chemotherapy drug in a phase 3 clinical trial survived longer, on average, than patients receiving other treatments. Researchers from Dana-Farber Cancer Institute reported the findings at the 2015 San Antonio Breast Cancer Symposium. The TH3RESA trial, which enrolled more than 600 participants in the U.S. and […]

View full entry

Tags: Breast Cancer, HER2-positive, metastatic, Metastatic Breast Cancer, News, Stages II-III Breast Cancer, T-DMI, TH3RESA trial, trastuzumab emtansine


October 9th, 2015

Abemaciclib Receives FDA Breakthrough Therapy Designation in Advanced Breast Cancer

By

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to abemaciclib, a cyclin-dependent kinase (CDK) 4 and 6 inhibitor, for patients with refractory hormone-receptor-positive (HR+) advanced or metastatic breast cancer. According to the FDA, Breakthrough Therapy Designation is a process designed to expedite the development and review of drugs that are intended […]

View full entry

Tags: abemaciclib, Breast Cancer, CDK, hormone-receptor positive, HR+, metastatic, Metastatic Breast Cancer, MONARCH 3, News, Recurrent Breast Cancer


September 29th, 2015

No Benefit with Addition of Onartuzumab to Taxol® with or without Avastin® in Triple-Negative Breast Cancer

By

The addition of the targeted therapy onartuzumab to Taxol® (paclitaxel) with or without Avastin® (bevacizumab) does not appear to help control disease or improve survival in patients with metastatic triple-negative breast cancer. These findings were published in the Annals of Oncology. The majority of breast cancers are hormone receptor-positive, meaning that the cancer cells are […]

View full entry

Tags: avastin, Breast Cancer, metastatic, Metastatic Breast Cancer, Onatuzumab, Taxol, triple negative


August 4th, 2015

Role of Tumor Size and Estrogen-Receptor Status in Decline in Breast Cancer Deaths

By

In light of a general decline in breast cancer death since the late 1980s, research has now turned to how type and stage of disease affect survival among different women. These findings, which considered tumor size and estrogen-receptor (ER) status, were reported in the Journal of Clinical Oncology. The death rate from breast cancer overall has […]

View full entry

Tags: Breast Cancer, Metastatic Breast Cancer, News, Recurrent Breast Cancer, Stages II-III Breast Cancer


June 3rd, 2015

Combination of Ibrance® plus Faslodex® Promising in Advanced Hormone-Positive Breast Cancer

By

The combination of Ibrance® (palbociclib) and Faslodex® (fulvestrant) appears to extend progression-free survival in women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER)-negative metastatic breast cancer. These findings were presented at 2015 Annual Meeting of the American Society of Clinical Oncology (May 29–June 2, Chicago, Illinois) and published in the New England […]

View full entry

Tags: Breast Cancer, ER-positive, Faslodex, HER2-negative, hormone-receptor positive, Ibrance, Metastatic Breast Cancer, News


May 26th, 2015

Platinum-Based Chemotherapy Active in Metastatic Triple-Negative Breast Cancer

By

Platinum-based chemotherapy appears active in the treatment of metastatic triple-negative breast cancers, particularly among patients with a BRCA1/2 mutation. These findings were reported in the Journal of Clinical Oncology. Breast cancers that are not stimulated to grow from exposure to estrogen or progesterone and are HER2 (human epidermal growth factor receptor)-negative are called triple-negative breast […]

View full entry

Tags: BRCA1/2, Breast Cancer, cisplatin, Metastatic Breast Cancer, News, Platinol, platinum based chemotherapy, triple negative